J
James M. Youakim
Researcher at ACADIA Pharmaceuticals Inc.
Publications - 23
Citations - 1265
James M. Youakim is an academic researcher from ACADIA Pharmaceuticals Inc.. The author has contributed to research in topics: Placebo & Medicine. The author has an hindex of 13, co-authored 18 publications receiving 1006 citations. Previous affiliations of James M. Youakim include Thomas Jefferson University & Cephalon.
Papers
More filters
Journal ArticleDOI
A normative study of the maintenance of wakefulness test (MWT).
Karl Doghramji,Merrill M. Mitler,R. Bart Sangal,Colin M. Shapiro,Sheila R. Taylor,Joyce A. Walsleben,Cynthia Belisle,Milton K. Erman,Rosa Hayduk,Rima Hosn,Edward B. O'Malley,JoAnne M. Sangal,Sharon L. Schutte,James M. Youakim +13 more
TL;DR: The maintenance of wakefulness test appears to be a useful procedure in differentiating groups with normal daytime wake tendency from those with impaired wake tendency and in identifying individuals with pathologic inability to remain awake under soporific circumstances.
Journal ArticleDOI
Efficacy and Safety of Adjunctive Brexpiprazole 2 mg in Major Depressive Disorder: A Phase 3, Randomized, Placebo-Controlled Study in Patients With Inadequate Response to Antidepressants
Michael E. Thase,James M. Youakim,Aleksandar Skuban,Mary Hobart,Carole Augustine,Peter Zhang,Robert D. McQuade,William H. Carson,Margaretta Nyilas,Raymond Sanchez,Hans Eriksson +10 more
TL;DR: Adjunctive brexpiprazole therapy demonstrated efficacy and was well tolerated in patients with major depressive disorder and inadequate response to ADTs.
Journal ArticleDOI
Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study.
Michael E. Thase,James M. Youakim,Aleksandar Skuban,Mary Hobart,Peter Zhang,Robert D. McQuade,Margaretta Nyilas,William H. Carson,Raymond Sanchez,Hans Eriksson +9 more
TL;DR: Bxpiprazole 3 mg demonstrated efficacy versus placebo in the efficacy population per final protocol in patients with major depressive disorder with inadequate response to ADTs.
Journal ArticleDOI
Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study
Clive Ballard,Carol Banister,Zunera Khan,Jeffrey L. Cummings,George Demos,Bruce Coate,James M. Youakim,Randall Owen,Srdjan Stankovic,Elaine B Tomkinson,Joanne McDermid,Delik Ocal,Ingelin Testad,Mustabshira A Qayyum,Polychronis Kemos,Olga Borejko,Maria Megalogeni,Ella V Brookes,Anya Petrava,Miguel Vasconcelos Da Silva,Kayleigh Nunez +20 more
TL;DR: Pimavanserin showed efficacy in patients with Alzheimer's disease psychosis at the primary endpoint (week 6) with an acceptable tolerability profile and without negative effect on cognition.
Journal ArticleDOI
Adjunctive Armodafinil for Major Depressive Episodes Associated With Bipolar I Disorder: A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Proof-of-Concept Study
Joseph R. Calabrese,Terence A. Ketter,James M. Youakim,Jane M. Tiller,Ronghua Yang,Mark A. Frye +5 more
TL;DR: In this proof-of-concept study, adjunctive armodafinil 150 mg/d appeared to improve depressive symptoms according to some, but not all, measures and was generally well tolerated in patients with bipolar depression.